Axial Spondyloarthritis Drug Market
Axial Spondyloarthritis Drug Market Size, Share & Trends Analysis Report by Type (Certolizumab Pegol, Etanercept Biosimilar, Ixekizumab, and Others), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast Period, (2026-2035)
Industry Overview
Axial spondyloarthritis drug market was valued at $920.5 million in 2025 and is projected to reach $1,723.4 million by 2035, growing at a CAGR of 6.5% during the forecast period (2026-2035). The global axial spondyloarthritis drug market is advancing steadily as healthcare systems and clinicians place greater emphasis on early diagnosis, timely therapeutic intervention, and long-term disease management to slow structural damage and preserve patient quality of life. Market growth is being supported by increasing awareness of inflammatory rheumatic diseases, improved diagnostic capabilities, and the expanding use of targeted biologic and advanced small-molecule therapies that address underlying inflammatory pathways. The growing adoption of tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) inhibitors, along with the emergence of novel therapeutic options, is enhancing treatment efficacy and expanding available choices for patients with both radiographic and non-radiographic axial spondyloarthritis. Demand is further reinforced by the rising prevalence of axial spondyloarthritis globally, increasing access to specialist rheumatology care, and the gradual expansion of reimbursement coverage for high-value biologic therapies in developed and select emerging markets.
Market Dynamics
Growing Focus on Early Diagnosis and Timely Therapeutic Intervention in Axial Spondyloarthritis
Healthcare systems and rheumatology specialists are increasingly emphasizing early diagnosis and prompt treatment initiation to limit disease progression, reduce irreversible structural damage, and improve long-term functional outcomes in patients with axial spondyloarthritis. Greater awareness among clinicians of non-radiographic axial spondyloarthritis, alongside improved imaging and diagnostic criteria, is leading to earlier patient identification and treatment eligibility. This shift toward early intervention is driving demand for effective pharmacological therapies that can control inflammation, alleviate chronic pain, and preserve spinal mobility. As payers and providers recognize the long-term economic and clinical benefits of early disease control, the adoption of disease-modifying drug therapies is emerging as a key factor supporting market growth.
Expanding Adoption of Targeted Biologic Therapies and Evolving Treatment Paradigms
Advances in immunology and drug development are reshaping axial spondyloarthritis treatment, with increasing adoption of targeted biologic agents such as TNF inhibitors and interleukin-17 inhibitors. These therapies offer improved efficacy, sustained symptom control, and better quality-of-life outcomes compared to conventional treatment approaches. In parallel, evolving treat-to-target strategies, growing use of real-world evidence, and expanding clinical guidelines are supporting more personalized and optimized treatment pathways. Pharmaceutical companies are also focusing on lifecycle management, biosimilar development, and next-generation therapies to enhance accessibility and cost efficiency. Together, these trends are driving continued expansion of innovative and value-driven drug solutions in the global axial spondyloarthritis drug market.
Market Segmentation
- Based on the type, the market is segmented into certolizumab pegol, etanercept biosimilar, ixekizumab, and others.
- Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Certolizumab Pegol Segment to Hold the Largest Share of the Market
The certolizumab pegol segment is expected to hold the largest share of the global axial spondyloarthritis drug market, driven by its strong clinical efficacy, differentiated safety profile, and broad applicability across diverse patient populations. As a PEGylated anti-TNF therapy lacking an Fc region, certolizumab pegol offers a reduced risk of placental transfer, making it a preferred option for women of childbearing age and patients requiring long-term treatment planning. Its proven effectiveness in controlling inflammation, reducing disease activity, and improving functional outcomes in both radiographic and non-radiographic axial spondyloarthritis has supported widespread clinical adoption. Additionally, established regulatory approvals, inclusion in major treatment guidelines, and increasing physician familiarity are reinforcing its sustained use as a first-line biologic therapy.
Hospital Pharmacies as the Leading Distribution Channel
Hospital pharmacies account for a significant share of the axial spondyloarthritis drug market, driven by their close integration with rheumatology departments and specialized care settings. Initiation of biologic and advanced therapies typically occurs in hospitals, where patients undergo diagnosis, treatment planning, and ongoing disease monitoring. Hospital pharmacies benefit from streamlined access to high-cost biologics, reimbursement coordination, and cold-chain infrastructure required for injectable therapies. Rising patient volumes, increasing use of infusion and specialty biologic drugs, and centralized procurement practices are further reinforcing the dominance of hospital pharmacies. Together, these factors position hospital pharmacies as a key distribution channel shaping overall market growth.
Regional Outlook
The global axial spondyloarthritis drug market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Expanding Healthcare Infrastructure and Treatment Access Across Asia-Pacific
Asia-Pacific is experiencing strong growth in the axial spondyloarthritis drug market as healthcare systems, pharmaceutical providers, and government agencies increase their focus on improving access to advanced rheumatology care. Rising investments in healthcare infrastructure, expanding availability of specialist services, and growing awareness of inflammatory musculoskeletal disorders are enabling earlier diagnosis and broader treatment adoption across both developed and emerging economies in the region. Improved access to MRI and rheumatology clinics is supporting timely identification of axial spondyloarthritis, including non-radiographic forms of the disease. In parallel, expanding reimbursement frameworks, greater penetration of biologic therapies, and the introduction of cost-effective biosimilars are accelerating market uptake.
North America Region Dominates the Market with Major Share
North America holds a leading position in the global axial spondyloarthritis drug market, supported by a well-established healthcare infrastructure and high awareness of inflammatory rheumatic diseases among clinicians and patients. The region benefits from early adoption of advanced biologic therapies, including TNF inhibitors and IL-17 inhibitors, alongside strong adherence to guideline-driven treatment protocols. Widespread access to rheumatology specialists, advanced imaging modalities, and structured referral pathways enables timely diagnosis and early initiation of targeted therapies. Favorable reimbursement frameworks, broad insurance coverage for biologics, and strong presence of leading pharmaceutical companies further support sustained drug uptake across the United States and Canada.
Market Players Outlook
The major companies operating in the global axial spondyloarthritis drug market include AbbVie Inc., Eli?Lilly and Company, Johnson?&?Johnson?Services, Inc., Novartis?AG, Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In July 2025, UCB expanded the clinical positioning of certolizumab pegol by reporting new real-world evidence data demonstrating sustained efficacy and long-term safety in patients with non-radiographic axial spondyloarthritis. The findings support earlier biologic intervention and reinforce the drug’s role in long-term disease management across diverse patient populations.
- In May 2025, Novartis advanced its axial spondyloarthritis portfolio with updated clinical trial results for ixekizumab, highlighting improved disease activity control and functional outcomes in patients with active disease who had an inadequate response to TNF inhibitors. The data further strengthened the adoption of IL-17 inhibitors as an effective alternative treatment option within evolving rheumatology guidelines.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global axial spondyloarthritis drug Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Axial Spondyloarthritis Drug Market Sales Analysis – Type | Distribution Channel ($ Million)
- Axial Spondyloarthritis Drug Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Axial Spondyloarthritis Drug Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Axial Spondyloarthritis Drug Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Axial Spondyloarthritis Drug Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Axial Spondyloarthritis Drug Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Axial Spondyloarthritis Drug Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Axial Spondyloarthritis Drug Market Revenue and Share by Manufacturers
- Axial Spondyloarthritis Drug Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AbbVie Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Eli?Lilly and Company
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson?&?Johnson?Services, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis?AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- AbbVie Inc.
- Key Company Analysis
- Global Axial Spondyloarthritis Drug Market Sales Analysis by Type ($ Million)
- Certolizumab Pegol
- Etanercept Biosimilar
- Ixekizumab
- Others
- Global Axial Spondyloarthritis Drug Market Sales Analysis by Distribution Channel ($ Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Analysis
- North American Axial Spondyloarthritis Drug Market Sales Analysis – Type | Distribution Channel | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Axial Spondyloarthritis Drug Market Sales Analysis – Type | Distribution Channel | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Axial Spondyloarthritis Drug Market Sales Analysis – Type | Distribution Channel | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Axial Spondyloarthritis Drug Market Sales Analysis – Type | Distribution Channel | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca Plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Boehringer Ingelheim International GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol?Myers Squibb Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Celgene Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reddy’s Laboratories Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Galapagos NV
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Gilead Sciences, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson Services, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Kyowa Kirin Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lupin Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sandoz Group AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- UCB S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. Global Axial Spondyloarthritis Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
2. Global Certolizumab Pegol Axial Spondyloarthritis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Etanercept Biosimilar Axial Spondyloarthritis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Ixekizumab Axial Spondyloarthritis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Others Biosimilar Axial Spondyloarthritis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Axial Spondyloarthritis Drug Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
7. Global Axial Spondyloarthritis Drug for Hospital Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Axial Spondyloarthritis Drug for Retail Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Axial Spondyloarthritis Drug for Online Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Axial Spondyloarthritis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
11. North American Axial Spondyloarthritis Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
12. North American Axial Spondyloarthritis Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
13. North American Axial Spondyloarthritis Drug Market Research and Analysis by Spectrum, 2025–2035 ($ Million)
14. European Axial Spondyloarthritis Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
15. European Axial Spondyloarthritis Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
16. European Axial Spondyloarthritis Drug Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
17. Asia-Pacific Axial Spondyloarthritis Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
18. Asia-Pacific Axial Spondyloarthritis Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
19. Asia-Pacific Axial Spondyloarthritis Drug Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
20. Rest of the World Axial Spondyloarthritis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
21. Rest of the World Axial Spondyloarthritis Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
22. Rest of the World Axial Spondyloarthritis Drug Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
1. Global Axial Spondyloarthritis Drug Market Share by Type, 2025 Vs 2035 (%)
2. Global Certolizumab Pegol Axial Spondyloarthritis Drug Market Share by Region, 2025 Vs 2035 (%)
3. Global Etanercept Biosimilar Axial Spondyloarthritis Drug Market Share by Region, 2025 Vs 2035 (%)
4. Global Ixekizumab Axial Spondyloarthritis Drug Market Share by Region, 2025 Vs 2035 (%)
5. Global Others Biosimilar Axial Spondyloarthritis Drug Market Share by Region, 2025 Vs 2035 (%)
6. Global Axial Spondyloarthritis Drug Market Share by Distribution Channel, 2025 Vs 2035 (%)
7. Global Axial Spondyloarthritis Drug for Hospital Pharmacies Market Share by Region, 2025 Vs 2035 (%)
8. Global Axial Spondyloarthritis Drug for Retail Pharmacies Market Share by Region, 2025 Vs 2035 (%)
9. Global Axial Spondyloarthritis Drug for Online Pharmacies Market Share by Region, 2025 Vs 2035 (%)
10. Global Axial Spondyloarthritis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
11. US Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
12. Canada Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
13. UK Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
14. France Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
15. Germany Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
16. Italy Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
17. Spain Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
18. Russia Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
19. Rest of Europe Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
20. India Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
21. China Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
22. Japan Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
23. South Korea Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
24. Australia and New Zealand Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
25. ASEAN Economies Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
26. Rest of Asia-Pacific Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
27. Latin America Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
28. Middle East and Africa Axial Spondyloarthritis Drug Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Axial Spondyloarthritis Drug Market in 2025 is estimated to be around $920.5 million.
North America holds the largest share in the Axial Spondyloarthritis Drug Market.
Leading players in the Axial Spondyloarthritis Drug Market include AbbVie Inc., Eli?Lilly and Company, Johnson?&?Johnson?Services, Inc., Novartis?AG, Pfizer Inc., among others.
The Axial Spondyloarthritis Drug Market is expected to grow at a CAGR of 6.5% from 2026 to 2035.
The Axial Spondyloarthritis Drug Market growth is driven by rising prevalence of inflammatory spinal disorders and increasing demand for advanced biologic and targeted therapies.
